India, Aug. 31 -- Inventiva S.A. (IVA), a clinical-stage biopharmaceutical company, on Monday announced the appointment of Chris Benecchi as Chief Operating Officer (COO).
Benecchi will oversee Inventiva's operational and commercial activities as the company prepares for topline data readout from the Phase 3 NATiV3 trial of Lanifibranor in metabolic dysfunction-associated steatohepatitis (MASH), expected in the fourth quarter of 2026. The company is targeting a potential U.S. launch in 2028, subject to regulatory approval.
Benecchi brings more than 30 years of experience in biopharmaceutical commercial, and operating roles. He recently served as Chief Executive Officer (CEO) of Motric Bio and previously held COO, Chief Business Officer an...